TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3306781
Drug: Iothalamate meglumine
Normalized name: Iothalamate Meglumine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iothalamate meglumine (ionic agent)
Study: 30107239
Drug: Standard home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard home oxygen therapy management
Study: 26429200
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day with ubiquinol supplementation
Study: 25265769
Drug: Intrathecal hyperbaric
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal hyperbaric bupivacaine 10 mg plus fentanyl 10 g
Study: 25265769
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 11 mg plus fentanyl 10 g
Study: 25265769
Drug: Intrathecal levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal levobupivacaine 11 mg plus fentanyl 10 g
Study: 22430286
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) with drug-eluting stent
Study: 18779612
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg/d orally)
Study: 18779612
Drug: Vinorelbine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine (30 mg/m2 infusion on days 1 and 8 of a 21-day cycle)
Study: 15929952
Drug: Prednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (30 mg q.d. for 2 weeks)
Study: 3131470
Drug: Intravenous desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous desmopressin acetate (0.4 microgram/kg)
Study: 3131470
Drug: Intranasal drops
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal drops and intranasal spray of desmopressin acetate
Study: 3131470
Drug: Intravenous desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous desmopressin acetate
Study: 3131470
Drug: Euglobulin lysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglobulin lysis time, t-PA activity, t-PA antigen levels, and t-PA fast-acting inhibitor (PAI) level
Study: 30672235
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of superficial needling technique and mild moxibustion
Study: 15042531
Drug: Rituximab in
Normalized name: rituximab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab in combination with fludarabine and cyclophosphamide
Study: 15042531
Drug: Increased dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dosing intensity and frequency of rituximab
Study: 11377899
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (controls, Group 4)
Study: 9442547
Drug: Sulpiride (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (200 mg daily for 30 days)
Study: 7955519
Drug: HIV-1LAI recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1LAI recombinant gp160 (rgp160) vaccine, 50-micrograms doses
Study: 7955519
Drug: HIV-1LAI recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1LAI recombinant gp160 (rgp160) vaccine, Group 1 (0, 1, 2, and 5 months)
Study: 7955519
Drug: HIV-1LAI recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1LAI recombinant gp160 (rgp160) vaccine, Group 2 (0, 1, 2, 3, and 4 months)
Study: 31736069
Drug: Carbetocin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin (100 μg/mL intravenously)
Study: 31736069
Drug: Misoprostol (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (800 μg rectally)
Study: 28320406
Drug: Three-session manualised
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-session manualised psychosocial group intervention and BBV transmission information booklet plus treatment as usual (TAU)
Study: 29208190
Drug: Information booklet
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information booklet plus treatment as usual (TAU)
Study: 25569072
Drug: Hydrogen peroxide
Normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrogen peroxide and sodium hypochlorite solution (control)
Study: 22022214
Drug: Aflapin(®) 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflapin(®) 100 mg daily for 30 days
Study: 15988404
Drug: Antithyroid drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drugs (methimazole 5-20 mg/die/os) and diphosphonates (alendronate 10 mg/die/os)
Study: 15988404
Drug: Antithyroid drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drugs only
Study: 12629097
Drug: rhIGF‐I (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I (30 micro g/kg sc twice daily)
Study: 7698300
Drug: Control cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control cycles (CHOP chemotherapy)
Study: 2642668
Drug: Morphine-proglumide mixtures
Normalized name: proglumide
DrugBank: Proglumide (DB13431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-proglumide mixtures (proglumide doses per demand: 0, 50 micrograms, 100 micrograms, or 50 mg)
Study: 2642668
Drug: Morphine (demand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (demand dose 3 mg; infusion rate 0.36 mg/hr; lockout time 2 minutes; hourly maximum dose 15 mg/hr)
Study: 31924543
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks, IAI 2 mg every 8 weeks after 5 monthly doses
Study: 29888580
Drug: Methotrexate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (10 mg, once a week) and Celecoxib (0.2 g, once a day)
Study: 18840204
Drug: 24% oral
Normalized name: Entero VU, 24% oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24% oral sucrose solution
Study: 16861101
Drug: Risperidone (flexible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (flexible dosing starting at 0.02 mg/kg/day, titrated up to 0.06 mg/kg/day)
Study: 10755740
Drug: Morphine 0
Normalized name: morphine 0.23 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0 mg/70 kg
Study: 10755740
Drug: Morphine 4
Normalized name: morphine 4 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 4 mg/70 kg
Study: 10755740
Drug: Morphine 8
Normalized name: morphine 8 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 8 mg/70 kg
Study: 10755740
Drug: Morphine 16
Normalized name: morphine sulfate 16 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 16 mg/70 kg
Study: 10755740
Drug: Morphine 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 32 mg/70 kg
Study: 10755740
Drug: Morphine (lowest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (lowest and highest doses repeated)
Study: 8677754
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose LPS (1 microgram/ml)
Study: 8677754
Drug: Lower LPS
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower LPS concentration (1 ng/ml)
Study: 29336645
Drug: Supervised individually
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised individually tailored exercise program (4-6 weeks), aerobic endurance, muscle strength, and relaxation exercises, administered twice a week
Study: 23211420
Drug: LCPUFA (n-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCPUFA (n-3 long-chain polyunsaturated fatty acids) supplementation at 84 g/day from day 60 of gestation through 21-day lactation and until day 30 of second gestation
Study: 21769058
Drug: Nicotine (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (21 mg transdermal patch)
Study: 9042638
Drug: Interferon-alpha-2c plus
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha-2c plus standard induction chemotherapy (three cycles of cyclophosphamide/vincristine/doxorubicin and cisplatin/etoposide plus subcutaneous IFN-alpha-2c)
Study: 8198267
Drug: Epidural alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural alfentanil (1 mg along with 0.2 mg/h and 0.2-mg boluses on demand)
Study: 8198267
Drug: Subcutaneous alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous alfentanil (1 mg along with 0.2 mg/h and 0.2-mg boluses on demand)
Study: 3440099
Drug: N-desmethylclobazam (NDMC)
Normalized name: N-ethylurea
DrugBank: Norclobazam (DB17092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-desmethylclobazam (NDMC) 30 mg single dose
Study: 3440099
Drug: Clobazam 30
Normalized name: Clobazam
DrugBank: Clobazam (DB00349)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clobazam 30 mg single dose
Study: 27554227
Drug: Dexem group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexem group (15 mL of 0.75% ropivacaine plus dexmedetomidine, 1 µg/kg bolus, followed by 0.2 µg/kg/hour infusion)
Study: 7498356
Drug: Randomised consent
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised consent (for experimental therapy)
Study: 7498356
Drug: Randomised consent
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised consent (for standard therapy)
Study: 2031498
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment in TOHP (Trials of Hypertension Prevention)
Study: 2031498
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment in HPT (Hypertension Prevention Trial)
Study: 7214987
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg diazepam intravenous supplement
Study: 7214987
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo (solvent of diazepam only)
Study: 21109054
Drug: Sedative massage
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative massage
Study: 1715503
Drug: Digital rectal
Normalized name: BD Thermometer Digital Rectal (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rectal screening and prostate-specific antigen (PSA) measurement
Study: 22427481
Drug: IDX320 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX320 50 mg once daily for 3 days
Study: 22427481
Drug: IDX320 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX320 100 mg once daily for 3 days
Study: 22427481
Drug: IDX320 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX320 200 mg once daily for 3 days
Study: 22427481
Drug: IDX320 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX320 400 mg once daily for 3 days
Study: 22427481
Drug: IDX320 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX320 200 mg twice daily for 3 days
Study: 14656275
Drug: Newer drugs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer drugs added to carboplatin-paclitaxel (TC)
Study: 14656275
Drug: Anti-idiotype CA
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-idiotype CA 125 antibodies
Study: 14656275
Drug: Epidermal growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidermal growth factor receptor (EGFR) modulation
Study: 10606017
Drug: Commercial ELISA
Normalized name: pseudopterogorgia elisabethae extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial ELISA for detecting serum antibody to Neospora caninum
Study: 10606017
Drug: Immunofluorescent antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunofluorescent antibody test (IFAT)
Study: 1850971
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (2 g/day in three doses for 10 days)
Study: 7327785
Drug: Therapist directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist directed training with self-help materials plus 10 individual treatment sessions
Study: 27133225
Drug: DANCIN intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DANCIN intervention (30 minutes/twice-weekly sessions for 12 weeks)
Study: 15708031
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of viable bacille Calmette-Guérin (BCG)
Study: 15708031
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with BCG
Study: 10648270
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1000 mg Ca/d as calcium carbonate, 5 d/wk for 12 months)
Study: 3545718
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg bid)
Study: 31766273
Drug: Egg yolk
Normalized name: EGG YOLK
DrugBank: Egg yolk (DB10530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg yolk phospholipid drink containing 3 g of phospholipid bound choline
Study: 31766273
Drug: Control drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control drink with 3 g of choline bitartrate
Study: 16937475
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (20 mg omeprazole b.i.d., 1000 mg amoxicillin b.i.d., 500 mg clarithromycin b.i.d.)
Study: 16937475
Drug: Standard quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard quadruple therapy (20 mg omeprazole b.i.d., 1000 mg amoxicillin b.i.d., 240 mg colloidal bismuth subcitrate b.i.d., and 500 mg metronidazole b.i.d.)
Study: 16937475
Drug: Ampicillin-sulbactam-based quadruple
Normalized name: ampicillin / sulbactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-sulbactam-based quadruple therapy (375 mg sultamicillin b.i.d.)
Study: 15319615
Drug: Interviewer-administered telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-administered telephone surveys
Study: 15319615
Drug: Self-administered mail
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered mail surveys with telephone reminder calls
Study: 15319615
Drug: Self-administered mail
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered mail surveys
Study: 15319615
Drug: Both modes
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both modes of survey administration
Study: 11173173
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine tablets
Study: 26268935
Drug: Leflunomide 50
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leflunomide 50 mg/week (LEF50)
Study: 26268935
Drug: Leflunomide 10
Normalized name: leflunomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide 10 mg/day (LEF10)
Study: 16995975
Drug: ALSS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALSS treatment
Study: 12893079
Drug: Lower radiation
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower radiation dose to contralateral parotid glands
Study: 10860694
Drug: Connecta Clave(R)
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Connecta Clave(R) (CC(R))
Study: 7720142
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (GH) 0.2 IU/kg/d
Study: 29798127
Drug: Ketotifen 1
Normalized name: ketotifen 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 1 mg 2 times/day oral treatment
Study: 29798127
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatment (antitussive, expectorant, and inhaled corticosteroids)
Study: 21620644
Drug: 20% oral
Normalized name: K-Sol 20% Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% oral sucrose
Study: 19033369
Drug: Elagolix (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elagolix (50-200 mg daily or 100 mg twice daily for 7 days)
Study: 19033369
Drug: Elagolix (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elagolix (single oral dose of 25-400 mg)
Study: 15385103
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin 50 mg/m² every 28 days
Study: 15385103
Drug: Topotecan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1.5 mg/m² per day for 5 days every 21 days
Study: 15385103
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin 50 mg/m² every 28 days (for platinum-sensitive disease)
Study: 15385103
Drug: Topotecan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1.5 mg/m² per day for 5 days every 21 days (for platinum-sensitive disease)
Study: 15385103
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin 50 mg/m² every 28 days (for all randomized subjects)
Study: 15385103
Drug: Topotecan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1.5 mg/m² per day for 5 days every 21 days (for all randomized subjects)
Study: 11907946
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg E2/0.25 mg NETA
Study: 11907946
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg E2/0.5 mg NETA
Study: 7673613
Drug: omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 20 mg once daily for 8 weeks
Study: 31409606
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg once daily for 8 weeks
Study: 7673613
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg once daily for 6 weeks
Study: 7673613
Drug: omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 20 mg once daily for 6 weeks
Study: 7447829
Drug: Metrizamide 280
Normalized name: metrizamide
DrugBank: Metrizamide (DB01578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metrizamide 280 mg/ml
Study: 7447829
Drug: Metrizamide 180
Normalized name: metrizamide
DrugBank: Metrizamide (DB01578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metrizamide 180 mg/ml
Study: 28886907
Drug: qHPV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: qHPV vaccine (control)
Study: 26355492
Drug: i-gel size
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: i-gel size 1.5
Study: 26355492
Drug: i-gel size
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: i-gel size 2
Study: 26355492
Drug: i-gel size
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: i-gel size 2.5
Study: 26355492
Drug: i-gel size
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: i-gel size 3
Study: 21420586
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac 0.1% applied 2 hours before PRK
Study: 21420586
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac 0.1% applied every 6 hours for 2 days postoperatively
Study: 7751567
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy with PCR detection after 3 days
Study: 7751567
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy with PCR detection after 7 days
Study: 2839019
Drug: enalapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril (2.5 to 40 mg/day)
Study: 18209133
Drug: Cochlear implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implant activated (on)
Study: 18209133
Drug: Cochlear implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implant deactivated (off)
Study: 16545724
Drug: Once-daily filgrastim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily filgrastim at 400 microg/m(2)/d
Study: 16545724
Drug: Twice-daily filgrastim
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily filgrastim at 400 microg/m(2)/d
Study: 8659426
Drug: CAST with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAST with 150 ml of contrast material
Study: 8659426
Drug: CAST with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAST with 125 ml of contrast material
Study: 8659426
Drug: CAST with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAST with 100 ml of contrast material
Study: 8659426
Drug: Control with
Normalized name: Azo Bladder Control With Go Less
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control with 150 ml of contrast material
Study: 8659426
Drug: Control with
Normalized name: Azo Bladder Control With Go Less
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control with 100 ml of contrast material
Study: 3908884
Drug: Oestriol 3
Normalized name: Oestriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestriol 3 mg daily for 3 months
Study: 20658006
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (AsGaAl laser, 40mW power, 80J/cm² for 16 seconds at four selected points, one session)
Study: 15071488
Drug: Delapril-Manidipine combination
Normalized name: manidipine
DrugBank: Manidipine (DB09238)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delapril-Manidipine combination
Study: 15071488
Drug: Irbesartan-Hydrochlorothiazide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan-Hydrochlorothiazide combination
Study: 12479682
Drug: Drug trials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug trials in mania, specific interventions not detailed
Study: 12479682
Drug: Various treatments,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments, alone or in combination, specific interventions not detailed